The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma

Abstract

RRM1 polymorphisms as well as haplotypes showed an association with gemcitabine treatment efficacy and toxicity; therefore, they should be validated as potential markers for the prediction of clinical outcome in patients with MM.